British Patient Capital Commits $50.8 Million to Evolution Equity Partners’ Third Fund, Highlighting UK’s Cybersecurity Expertise

Evolution Equity Partners has received a $50.8 million commitment from British Patient Capital for their third fund. Evolution Equity Partners is a specialist technology investor that focuses on cybersecurity and enterprise software companies. The firm has made several successful investments in the past, including Quantexa, a global data and analytics software company that achieved unicorn status in 2023, and Panaseer, an enterprise security platform.

This latest investment by British Patient Capital follows a $35 million commitment to Evolution’s second fund in 2020. According to Robert Greenwood, Investment Director of Funds at British Patient Capital, the evolution of cybersecurity over the last two decades has been remarkable. He emphasized how cybersecurity has become a crucial application across all sectors as businesses strive to protect themselves, their customers, and their products. This investment highlights the UK’s leadership in cybersecurity innovation and its expertise in this valuable technology sector.

Richard Seewald, Founder and Managing Partner at Evolution Equity Partners, expressed excitement about partnering with British Patient Capital and NSSIF to support UK-based cybersecurity companies. Seewald stressed the critical importance of cybersecurity to the safety of UK-based enterprises, governments, and consumers. He highlighted how the current environment underscores the necessity of next-generation technology that can defend and protect society and our way of life.

The goal of this partnership is to provide these companies with capital, knowledge, tools, and strategies to drive performance and success in the global market. Through this investment by British Patient Capital, Evolution Equity Partners aims to continue its focus on investing in innovative cybersecurity solutions that can help UK businesses thrive in today’s fast-changing world.